You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

Details for Patent: 6,987,103

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 6,987,103 protect, and when does it expire?

Patent 6,987,103 protects SYNRIBO and is included in one NDA.

This patent has twenty-one patent family members in twelve countries.

Summary for Patent: 6,987,103

Title:	Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents
Abstract:	The present invention concerns a method of treating chronic myelogenous leukemia, a related myeloproliferative disorder or a Ph-positive acute lymphocytic leukemia in a subject animal, comprising: (a) selecting or identifying an animal suffering from chronic myelogenous leukemia or a related myeloproliferative disorder and showing resistance or intolerance to treatment with STI571; and (b) administering to the animal homoharringtonine. In a preferred embodiment, the animal is a human being.
Inventor(s):	Robin; Jean-Pierre (Charlottesville, VA), Mahon; Francois-Xavier (Bordeaux, FR), Maisonneuve; Herve (La Roche sur Yon, FR), Maloisel; Frederick (Illkirch Graffenstaden, FR), Blanchard; Julie (Rouillon, FR)
Assignee:	Stragen Pharma S.A. (Geneva, CH)
Application Number:	10/397,267
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 6,987,103

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Teva Pharms Intl	SYNRIBO	omacetaxine mepesuccinate	POWDER;SUBCUTANEOUS	203585-001	Oct 26, 2012		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 6,987,103

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	451106	⤷ Sign Up
Austria	548041	⤷ Sign Up
Australia	2002337410	⤷ Sign Up
Canada	2459822	⤷ Sign Up
Cyprus	1109799	⤷ Sign Up
Cyprus	1112817	⤷ Sign Up
Germany	60234708	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.